Diligence memo · auto-generated · as of July 2, 2026
Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Sonnet BioTherapeutics Holdings, Inc. operates in Biotechnology, based in PRINCETON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sonnet BioTherapeutics Holdings, Inc. has raised $25M in disclosed capital across 11 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.0M on 2017-05-04.
Most recent recorded round closed around 2024-12-10.
Valuation (modeled)modeled
Provath models Sonnet BioTherapeutics Holdings, Inc. at approximately $17M (range $4.3M–$32M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.37× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 19 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 72% of Biotechnology peers (4293 compared).
Modeled value ranks above 26% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.